Company No:
Contents
| DIRECTORS | A Hersham (Appointed 15 September 2023) |
| Dr L Osherovich (Appointed 15 September 2023) |
| REGISTERED OFFICE | 25 Randolph Crescent |
| London | |
| W9 1DP | |
| United Kingdom |
| COMPANY NUMBER | 15140523 (England and Wales) |
| ACCOUNTANT | Gravita Essex Limited |
| Treviot House | |
| 186-192 High Road | |
| Ilford | |
| Essex | |
| IG1 1LR | |
| United Kingdom |
| Note | 30.09.2024 | |
| £ | ||
| Fixed assets | ||
| Intangible assets | 3 |
|
| 70,293 | ||
| Current assets | ||
| Cash at bank and in hand |
|
|
| 120,272 | ||
| Creditors: amounts falling due within one year | 4 | (
|
| Net current assets | 118,592 | |
| Total assets less current liabilities | 188,885 | |
| Net assets |
|
|
| Capital and reserves | ||
| Called-up share capital |
|
|
| Equity reserve |
|
|
| Profit and loss account | (
|
|
| Total shareholders' funds |
|
Directors' responsibilities:
The financial statements of Nonsense Therapeutics Ltd (registered number:
|
A Hersham
Director |
The principal accounting policies are summarised below. They have all been applied consistently throughout the financial period, unless otherwise stated.
Nonsense Therapeutics Ltd (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is 25 Randolph Crescent, London, W9 1DP, United Kingdom.
The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.
The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.
The directors have assessed the Balance Sheet and likely future cash flows at the date of approving these financial statements. The directors have a reasonable expectation that the Company has adequate resources to continue in operational existence and to meet its financial obligations as they fall due for at least 12 months from the date of signing these financial statements. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.
Exchange differences are recognised in the Profit and Loss Account in the period in which they arise except for exchange differences arising on gains or losses on non-monetary items which are recognised in the Statement of Comprehensive Income.
| Other intangible assets |
|
Financial assets and financial liabilities are recognised when the Company becomes a party to the contractual provisions of the instrument.
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities.
Financial assets and liabilities are only offset in the Balance Sheet when, and only when there exists a legally enforceable right to set off the recognised amounts and the Company intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.
| Period from 15.09.2023 to 30.09.2024 |
|
| Number | |
| Monthly average number of persons employed by the Company during the period, including directors |
|
| Other intangible assets | Total | ||
| £ | £ | ||
| Cost | |||
| At 15 September 2023 |
|
|
|
| Additions |
|
|
|
| At 30 September 2024 |
|
|
|
| Accumulated amortisation | |||
| At 15 September 2023 |
|
|
|
| Charge for the financial period |
|
|
|
|
|
|
||
| At 30 September 2024 |
|
|
|
| Net book value | |||
| At 30 September 2024 |
|
|
| 30.09.2024 | |
| £ | |
| Other creditors |
|